Immunic (NASDAQ:IMUX) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Immunic (NASDAQ:IMUX) in a report issued on Friday,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock.

Several other equities research analysts have also commented on IMUX. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Immunic in a report on Thursday. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research note on Monday, February 10th. One analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Immunic currently has a consensus rating of “Buy” and an average price target of $12.67.

Immunic Stock Up 6.6 %

IMUX stock opened at $1.26 on Friday. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11. The firm’s fifty day simple moving average is $1.02 and its 200-day simple moving average is $1.26.

Hedge Funds Weigh In On Immunic

Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. acquired a new stake in Immunic in the fourth quarter valued at approximately $37,000. Virtu Financial LLC acquired a new stake in Immunic in the 3rd quarter valued at $50,000. HB Wealth Management LLC purchased a new stake in Immunic in the 4th quarter worth $81,000. Barclays PLC acquired a new position in Immunic during the fourth quarter worth $84,000. Finally, Jane Street Group LLC lifted its holdings in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.